ALLINQUANTB., HANTRAYEP., MAILLEUXP., MOYAK., BOUILLOTC., PROCHIANTZA.1995. Downregulation of amyloid precursor protein inhibits neurite outgrowth in vitro. J. Cell Biol., 128:919–927.
2.
ALVAREZ-ERVITIL., SEOWY., YINH., BETTSC., LAKHALS., WOODM.J.A. 2011. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nature Biotech., 29:341–345.
3.
BONGARTZJ.P., AUBERTINA.M., MILHAUDP.G., LEBLEUB.1994. Improved biological activity of antisense oligonucleotides conjugated to a fusogenic peptide. Nucleic Acids Res., 22:4681–4688.
4.
BURRERR., NEUMANB.W., TINGJ.P.C., STEIND.A., MOULTONH.M., IVERSENP.L., KUHNP., BUCHMEIERM.J.2007. Antiviral effects of antisense morpholino oligomers in murine coronavirus infection models. J. Virol., 81:5637–5648.
5.
CIRAKS., ARECHAVALA-GOMEZAV., GUGLIERIM., FENGL., TORELLIS., ANTHONYK., ABBSS., GARRALDAM.E., BOURKEJ., WELLSD.J.et al.2011. Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open label, phase 2, dose-escalation study. Lancet, 378:595–605.
DEAST.S., BENNETTC.J., JONESS.A., TILGNERM., RENP., BEHRM.J., STEIND.A., IVERSENP.L., KRAMERL.D., BERNARDK.A.et al.2007. In vitro resistance selection and in vivo efficacy of morpholino oligomers against West Nile virus. Antimicrobial Agents Chemother., 51:2470–2482.
8.
DIVITAG., HEITZF., MORRISM.C., ALDRIAN-HERRADAG.2009. Cell-penetrating peptides for intracellular delivery of moleculesU. S. Patent Application 2009/0156503.
9.
DUL., KAYALIR. C. B., FIKEF., HUH., IVERSENP.L., GATTIR.A.2011. Arginine-rich cell-penetrating peptide dramatically enhances AMO-mediated ATM aberrant splicing correction and enables delivery to brain and cerebellum. Hum. Mol. Gen., 20:3151–3160.
10.
EL ANDALOUSSIS., LEHTOT., MÄGERI., ROSENTHAL-AIZMANK., OPREAI.I., SIMONSONO.E., SORKH., EZZATK., COPOLOVICID.-M., KURRIKOFFK.et al.2011. Design of a peptide-based vector, PepFect6, for efficient delivery of siRNA in cell culture and systemically in vivo. Nucleic Acids Res., 39:3972–3987.
11.
EZZATK., EL ANDALOUSSIS., ABDOR., LANGELU.2010. Peptide-based matrices as drug delivery vehicles. Curr. Pharm. Design, 16:1167–1178.
12.
EZZATK., EL ANDALOUSSIS., ZAGHLOULE.M., LEHTOT., LINDBERGS., MORENOP.M.D., VIOLAJ.R., MAGDYT., ABDOR., GUTERSTAMP.et al.2011. PepFect 14, a novel cell-penetrating peptide for olignucleotide delivery in solution and as solid formulation. Nucleic Acids Res., 39:5284–5298.
13.
FABANIM.M., ABREU-GOODGERC., WILLIAMSD., LYONSP.A., TORRESA., SMITHK.G.C., ENRIGHTA.J., GAITM.J., VIGORITOE.2010. Efficient inhibition of miR-155 function in vivo by Peptide Nucleic Acids. Nucleic Acids Res., 38:4466–4475.
14.
GOUNE.A., PILLOWT.H., JONESL.R., ROTHBARDJ.B., WENDERP.A.2006. Molecular transporters: synthesis of oligoguanidinium transporters and their application to drug delivery and real-time imaging. ChemBioChem, 7:1497–1515.
15.
HEIDELJ.D., YUZ., LIUJ.Y., RELES.M., LIANGY., ZEIDENR.K., KORNBRUSTD.J., DAVISM.E.2011. Administration in non-human primates of escalating intravenous dosed of targeted nanoparticles containing ribonucleotides reductase subunit M2 siRNA. Proc. Natl. Acad. Sci. U. S. A., 104:5715–5721.
16.
HENKEE., PERKJ., VIDERJ., DE CANDIAP., CHINY., SOLITD.B., PONOMAREVV., CATEGNIL., MANOVAK., ROSENN.et al.2008. Peptide-conjugated antisense oligonucleotides for targeted inhibition of a transcriptional regulator in vivo. Nature Biotech., 26:91–100.
17.
HSUT., MITRAGOTRIS.2011. Delivery of siRNA and other macromolecules into skin and cells using a peptide enhancer. Proc. Nat. Acad. Sci. U. S. A., 108:15816–15821.
18.
JÄRVERP., MÄGERI., LANGELU.2010. In vivo biodistribution and efficacy of peptide mediated delivery. Trends Pharmacol. Sci., 31:528–535.
19.
KUMARP., WUH., MCBRIDEJ.L., JUNGK.E., KIMM.H., DAVIDSONB.L., LEES.K., SHANKARP., MANJUNATHN.2007. Transvascular delivery of small interfering RNA to the central nervous system. Nature, 448:39–43.
LANGELU.2007. Handbook of Cell-Penetrating Peptides. CRC Press: Boca Raton, 1–600.
22.
LANGELU.2011. Cell-penetrating Peptides. Methods and Protocols. Springer: New York, 1–586.
23.
LEHTOT., SIMONSONO.E., MÄGERI., EZZATK., SORKH., COPOLOVICID.-M., VIOLAJ.R., ZAGHLOULE.M., LUNDINP., MORENOP.M.D.et al.2011. A peptide-based vector for efficient gene transfer in vitro and in vivo. Mol. Ther., 19:1457–1467.
24.
MAIERM.A., ESAUC.C., SIWKOWSKIA.M., WANCEWICZE.V., ALBERTSHOFERK., KINBERGERG.A., KADABAN.S., WATANABET., MANOHARANM., BENNETTC.F.et al.2006. Evaluation of basic amphipathic peptides for cellular delivery of antisense peptide nucleic acids. J. Med. Chem., 49:2534–2542.
25.
MARGUSH., PADARIK., POOGAM.2012. Cell-penetrating peptides as versatile vehicles for oligonucleotide delivery. Mol. Ther. doi:10.1038/mt.2011.284.
26.
MELBYEB.L., WELLERD.D., HASSINGERJ.N., REEVESM.D., LOVEJOYC.E., IVERSENP.L., GELLERB.L.2010. Cationic phosphordiamidate morpholino oligomers efficiently prevent growth of Escherischia coli in vitro and in vivo. J. Antimicrob. Chemother., 65:98–106.
27.
MICHIUEH., EGUCHIA., SCADENGM., DOWDYS.F.2009. Induction of in vivo synthetic lethal RNAi responses to treat glioblastoma. Cancer Biol. Ther., 8:2304–2311.
28.
MORRISM.C., GROSE., ALDRIAN-HERRADAG., CHOOBM., ARCHDEACONJ., HEITZF., DIVITAG.2007. A non-covalent peptide-based carrier for in vivo delivery of DNA mimics. Nucleic Acids Res., 35:e49.
29.
MOULTONH.M., MOULTONJ.D.2008. Antisense Morpholino Oligomers and Their Peptide Conjugates. Therapeutic Oligonucleotides. KurreckJ.Royal Society of Chemistry: Cambridge, UK, 43–79.
30.
MOULTONH.M., MOULTONJ.D.2010. Morpholinos and their peptide conjugates: therapeutic promise and challenge for Duchenne muscular dystrophy. Biochim. Biophys. Acta, 12:2296–2303.
31.
OGRISM, WAGNERE.2011. To be targeted: is the magic bullet concept a viable option for synthetic nucleic acid therapeutics? Hum. Gene Ther., 22:799–807.
32.
PASTORF., KOLONIASD., GIANGRANDEP.H., GILBOAE.2010. Induction of tumour immunity by targeted inhibition of nonsense-mediated mRNA decay. Nature, 465:227–230.
33.
PULFORDB., REIMN., BELLA., VEATCHJ., FORSTERG., BENDERH., MEYERETTC., HAFEMANS., MICHELB., JOHNSONT.et al.2010. Liposome-siRNA-peptide complexes cross the blood–brain barrier and significantly decrease PrPc on neuronal cells and PrPRes in infected cell cultures. PloS One, 5:e11085.
34.
ROGERSF.A., LINS.S., HEGAND.C., KRAUSED.S., GLAZERP.M.2011. Targeted gene modification of hematopoietic progenitor cells in mice following systemic administration of a PNA-peptide conjugate. Mol. Ther., 20:109–118.
35.
RYDSTRÖMA., DESHAYESS., KONATEK., CROMBEZL., PADARIK., BOUKHADDAOUIH., ALDRIANG., POOGAM., DIVITAG. 2011. Direct translocation as major cellular uptake for CADY self-assembling peptide-based nanoparticles. PloS One, 6:e25924.
36.
SONS., HWANGD.W., SINGHAK., JEONGJ.H., PARKT.G., LEED.S., KIMW.J.2011. RVG peptide tethered bioreducible polyethyleneimine for gene delivery to brain. J. Control. Release, 155:18–25.
37.
STAQUICINIF.I., OZAWAM.G., MOYAC.A., DRIESSENW.H.P., BARBUE.M., NISHIMORIH., SOGHOMONYANS., FLORESL.G.2ND, LIANGX., PAOLILLOVet al.2011. Systemic combinatorial peptode selection yields a non-canonical iron-mimicry mechanism for targeting tumors in a mouse model of human glioblastoma. J. Clin. Invest., 121:161–173.
38.
STAQUICINIF.I., SIDMANR.L., ARAPW., PASQUALINIR.2010. Phage display technology for stem cell delivery and systemic therapy. Adv. Drug Deliv. Rev., 62:1213–1216.
39.
TORRESA.G., FABANIM.M., VIGORITOE., WILLIAMSD., AL-OBAIDIN., WOJCIECHOWSKIF., HUDSONR.H.E., SEITZO., GAITM.J.2011. Chemical structure requirements and cellular targeting of microRNA-122 by peptide nucleic acids anti-miRs. Nucleic Acids Res. doi:10.1093/nar/gkr885.
40.
VAN DEN BERGA., DOWDYS.F.2011. Protein transduction domain delivery of therapeutic macromolecules. Curr. Opin. Biotechnol., 22:888–893.
41.
WANCEWICZE.V., MAIERM.A., SIWKOWSKIA.M., ALBERTSHOFERK., WINGERT.M., BERDEJAA., GAUSH., VICKERST.A., BENNETTC.F., MONIAB.P.et al.2010. Peptide nucleic acids conjugated to short basic peptide show improved pharmacokinetics and antisense activity in adipose tissue. J. Med. Chem., 53:3919–3926.
42.
WIDRICKJ.J., JIANGS., CHOIS.J., KNUTHS.T., MORCOSP.A.2011. An octaguanidine-morpholino oligo conjugate improves muscle function of mdx mice. Muscle Nerve, 44:563–570.
43.
WOODM.J.A.2010. Towards an oligonucleotide therapy for Duchenne muscular dystrophy: a complex development challenge. Sci. Trans. Med., 2:25ps15.
